BiotechTube

Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable Tablet

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Jun 8, 2022 → Apr 23, 2023

NCT ID
NCT04485039

About Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable Tablet

Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable Tablet is a approved stage product being developed by SIGA Technologies for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT04485039. Target conditions include Smallpox.

What happened to similar drugs?

2 of 7 similar drugs in Smallpox were approved

Approved (2) Terminated (0) Active (5)
🔄FD MVA-BNBavarian NordicPhase 3
🔄IMVAMUNE®Bavarian NordicPhase 3
🔄ACAM2000Emergent BioSolutionsPhase 3
✅Vaccination with ACAM2000Emergent BioSolutionsApproved
🔄tecovirimatSIGA TechnologiesPhase 3
🔄TPOXXSIGA TechnologiesPhase 3
✅TpoxxSIGA TechnologiesApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04485039ApprovedCompleted

Competing Products

20 competing products in Smallpox

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
35
MVA (smallpox vaccine)SanofiPhase 1
21
ACAM3000 MVA VaccineSanofiPhase 1
29
MVA Smallpox vaccine + PlaceboSanofiPhase 2
35
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
27
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
32
MVA-BNBavarian NordicPhase 1
26
IMVAMUNE®Bavarian NordicPhase 2
32
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
32
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
FD MVA-BNBavarian NordicPhase 3
37
IMVAMUNE®Bavarian NordicPhase 3
37
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
32
Elstree-BNBavarian NordicPhase 1
26
ACAM2000Emergent BioSolutionsPhase 3
30
VIGIVEmergent BioSolutionsPre-clinical
23
ACAM2000® smallpox vaccineEmergent BioSolutionsPre-clinical
16
BrincidofovirEmergent BioSolutionsPhase 1
19